Original Contribution

Colon/Small Bowel

Risk of Clostridium difficile Infection in Patients With Celiac Disease: A Population-Based Study

  • The American Journal of Gastroenterology volume 112, pages 18781884 (2017)
  • doi:10.1038/ajg.2017.400
  • Download Citation
Received:
Accepted:
Published:

Subjects

Abstract

Objectives:

Patients with celiac disease are at increased risk for infections such as tuberculosis, influenza, and pneumococcal pneumonia. However, little is known about the incidence of Clostridium difficile infection (CDI) in patients with celiac disease.

Methods:

We identified patients with celiac disease based on intestinal biopsies submitted to all pathology departments in Sweden over a 39-year period (from July 1969 through February 2008). We compared risk of CDI (based on stratified Cox proportional hazards models) among patients with celiac disease vs. without celiac disease (controls) matched by age, sex, and calendar period.

Results:

We identified 28,339 patients with celiac disease and 141,588 controls; neither group had a history of CDI. The incidence of CDI was 56/100,000 person-years among patients with celiac disease and 26/100,000 person-years among controls, yielding an overall hazard ratio (HR) of 2.01 (95% confidence interval (CI), 1.64–2.47; P<0.0001). The risk of CDI was highest in the first 12 months after diagnosis of celiac disease (HR, 5.20; 95% CI, 2.81–9.62; P<0.0001), but remained high, compared to that of controls, 1–5 years after diagnosis (HR, 1.85; 95% CI, 1.22–2.81; P=0.004). Among 493 patients with CDI, antibiotic data were available for 251; there were no significant differences in prior exposures to antibiotics between patients with celiac disease and controls.

Conclusions:

In a large population-based cohort study, patients with celiac disease had significantly higher incidence of CDI than controls. This finding is consistent with prior findings of higher rates of other infections in patients with celiac disease, and suggests the possibility of altered gut immunity and/or microbial composition in patients with celiac disease.

  • Subscribe to The American Journal of Gastroenterology for full access:

    $870

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , . Increased risk of hospital admission for influenza in patients with celiac disease: a nationwide cohort study in Sweden. Am J Gastroenterol 2010;105:2465–2473.

  2. 2.

    , , et al. Pneumococcal infection in patients with coeliac disease. Eur J Gastroenterol Hepatol 2008;20:624–628.

  3. 3.

    , et al. Risk of community-acquired pneumonia among patients with coeliac disease compared to the general population: a population based cohort study. Gut 2015;64:A129–A130.

  4. 4.

    , , et al. Coeliac disease and risk of tuberculosis: a population based cohort study. Thorax 2007;62:23–28.

  5. 5.

    , , et al. Coeliac disease and risk of sepsis. Gut 2008;57:1074–1080.

  6. 6.

    , , et al. Causes of death in patients with celiac disease in a population-based swedish cohort. Arch Intern Med 2003;163:1566–1572.

  7. 7.

    , , et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–834.

  8. 8.

    , . Clostridium difficile infection. N Engl J Med 2015;372:1539–1548.

  9. 9.

    , , et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013;56:1401–1406.

  10. 10.

    , , . Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008;57:205–210.

  11. 11.

    , , et al. Clostridium difficile and pediatric inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2219–2225.

  12. 12.

    , . Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis 2005;11:685–695.

  13. 13.

    , , . Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol 2017;15:166–174.

  14. 14.

    , , et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443–1450.

  15. 15.

    , , et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. BMC Gastroenterol 2013;13:109.

  16. 16.

    , , et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS ONE 2012;7:e33387.

  17. 17.

    , , et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Intern Med 2013;159:169–175.

  18. 18.

    , , et al. Validation study of villous atrophy and small intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol 2009;9:19.

  19. 19.

    , , et al. The association between socioeconomic status and the symptoms at diagnosis of celiac disease: a retrospective cohort study. Therap Adv Gastroenterol 2016;9:495–502.

  20. 20.

    , , et al. Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am J Epidemiol 2013;178:1721–1730.

  21. 21.

    , , et al. Risk of dementia in patients with celiac disease: a population-based cohort study. J Alzheimers Dis 2015;49:179–185.

  22. 22.

    , , et al. Small-intestinal histopathology and mortality risk in celiac disease. JAMA 2009;302:1171–1178.

  23. 23.

    , , et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst 2011;103:436–444.

  24. 24.

    , , et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726–735.

  25. 25.

    , , et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol 2015;7:491–508.

  26. 26.

    , , et al. Gut microbiota composition and Clostridium difficile infection in hospitalized elderly individuals: a metagenomic study. Sci Rep 2016;6:25945.

  27. 27.

    , , et al. The impact of Clostridium difficile Infection on pediatric inflammatory bowel disease. J Pediatr 2009;154:854–858.

  28. 28.

    , , et al. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol 2009;62:264–269.

  29. 29.

    , , . Differences between the fecal microbiota of coeliac infants and healthy controls. Curr Issues Intest Microbiol 2007;8:9–14.

  30. 30.

    , , et al. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr 2009;102:1154–1160.

  31. 31.

    , , et al. The susceptibility of celiac disease intestinal microbiota to Clostridium difficile infection. Am J Gastroenterol 2015, 1740–1741.

  32. 32.

    , , et al. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004;329:716 LP–716 L9.

  33. 33.

    , , et al. Validity and reliability of administrative coded data for the identification of hospital-acquired infections: an updated systematic review with meta-analysis and meta-regression analysis. Health Serv Res, doi: 10.1111/1475-6773.12691 [e-pub ahead of print 11 April 2017].

  34. 34.

    , , et al. Use of proton pump inhibitors and subsequent risk of celiac disease. Dig Liver Dis 2014;46:36–40.

  35. 35.

    , , et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011–1019.

  36. 36.

    , , et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:1359–1367.

  37. 37.

    , , et al. Receipt of antibiotics in hospitalized patients and risk for Clostridium difficile infection in subsequent patients who occupy the same bed. JAMA Intern Med 2016;176:1801–1808.

Download references

Author information

Affiliations

  1. Department of Medicine, Celiac Disease Center, Columbia University Medical Center, New York, New York, USA

    • Benjamin Lebwohl
    • , Yael R Nobel
    • , Peter H R Green
    •  & Jonas F Ludvigsson
  2. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA

    • Benjamin Lebwohl
  3. New York University Langone Medical Center, New York, New York, USA

    • Martin J Blaser
  4. Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

    • Jonas F Ludvigsson
  5. Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden

    • Jonas F Ludvigsson

Authors

  1. Search for Benjamin Lebwohl in:

  2. Search for Yael R Nobel in:

  3. Search for Peter H R Green in:

  4. Search for Martin J Blaser in:

  5. Search for Jonas F Ludvigsson in:

Competing interests

Guarantor of the article: Benjamin Lebwohl, MD, MS.

Specific author contributions: Study concept and design: B.L., P.H.R.G., and J.F.L; acquisition of data: B.L. and J.F.L; analysis and interpretation of data: B.L., Y.R.N., P.H.R.G., M.J.B., and J.F.L; drafting of the manuscript: B.L. and Y.R.N; critical revision of the manuscript for important intellectual content: B.L., Y.R.N., P.H.R.G., M.J.B., and J.F.L; statistical analysis: B.L. and J.F.L.

Financial support: NIH R01 DK090989 (Martin Blaser).

Potential competing interests: None.

Corresponding author

Correspondence to Benjamin Lebwohl.

Supplementary information

SUPPLEMENTARY MATERIAL is linked to the online version of the paper at http://www.nature.com/ajg